Journal
EXPERT OPINION ON DRUG DISCOVERY
Volume 3, Issue 1, Pages 99-114Publisher
INFORMA HEALTHCARE
DOI: 10.1517/17460441.3.1.99
Keywords
cancer; Hsp90; neurodegeneration; purine-scaffold
Categories
Funding
- Susan G Komen Breast Cancer Foundation
- SynCure Cancer Research Foundation
- Byrne Fund of MSKCC
- Geoffrey Beene Cancer Research Center of MSKCC
- Institute for the Study of Aging (Alzdiscovery award)
- Manhasset Women's Coalition Against Breast Cancer
- National Institute of Aging
Ask authors/readers for more resources
The heat-shock protein 90 (Hsp90), an important target in cancer and other diseases, has become recently the focus of several drug discovery and development efforts. The initially identified natural-product inhibitors of Hsp90, such as geldanamycin, played a major role in elucidating its biological function and in determining its clinical relevance. Upcoming synthetic inhibitors, such as the purine-scaffold class, furthered our understanding on Hsp90 in cancer and neurodegenerative diseases and delivered what are promised to be clinical candidates with favorable pharmacologic profiles. This review intends to inform the reader on efforts ranging from the discovery of purine-scaffold Hsp90 inhibitors to their clinical translation as well as on their use as chemical tools to dissect the roles of Hsp90 in pathogenic systems.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available